Author: Nakhlband, Ailar; Fakhari, Ali; Azizi, Hosein
Title: Interferon-beta offers promising avenues to COVID-19 treatment: a systematic review and meta-analysis of clinical trial studies Cord-id: go9yq2zx Document date: 2021_2_15
ID: go9yq2zx
Snippet: Severe acute respiratory syndrome coronavirus 2 principally weakens the hosts’ innate immune system by impairing the interferon function and production. Type I interferons (IFNs) especially IFN-β are best known for their antiviral activities. IFNs accompanied by the standard care protocols have opened up unique opportunities for treating the coronavirus disease 2019 (COVID-19). The databases including PubMed, SCOPUS, EMBASE, and Google Scholar were searched up to October 30, 2020. The primary
Document: Severe acute respiratory syndrome coronavirus 2 principally weakens the hosts’ innate immune system by impairing the interferon function and production. Type I interferons (IFNs) especially IFN-β are best known for their antiviral activities. IFNs accompanied by the standard care protocols have opened up unique opportunities for treating the coronavirus disease 2019 (COVID-19). The databases including PubMed, SCOPUS, EMBASE, and Google Scholar were searched up to October 30, 2020. The primary and secondary outcomes were considered discharge and mortality, respectively. The abovementioned outcomes of standard care protocol were compared with the standard care plus IFN-β in the confirmed COVID-19 patients. Out of 356 records identified, 12 randomized clinical trial studies were selected for full-text screening. Finally, 5 papers were included in the systematic review and 3 papers in the meta-analysis. The average mortality rate was reported as 6.195% and 18.02% in intervention and control groups, respectively. Likewise, the median days of hospitalization were lower in the intervention group (9 days) than the control group (12.25 days). According to meta-analysis, IFN-β was found to increase the overall discharge rate (RR = 3.05; 95% CI: 1.09–5.01). Our findings revealed that early administration of IFN-β in combination with antiviral drugs is a promising therapeutic strategy against COVID-19.
Search related documents:
Co phrase search for related documents- abstract title and lopinavir combination: 1
- abstract title and lopinavir ritonavir: 1, 2
- activity production and acute ards respiratory distress syndrome: 1
- activity production and adaptive immune response: 1
- acute ards respiratory distress syndrome and adaptive immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- acute ards respiratory distress syndrome and lopinavir combination: 1, 2, 3, 4
- acute ards respiratory distress syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute ards respiratory distress syndrome and lopinavir ritonavir antiviral drug: 1
- acute ards respiratory distress syndrome and lopinavir ritonavir antiviral medication: 1
- acute ards respiratory distress syndrome and lopinavir ritonavir hydroxychloroquine: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- acute ards respiratory distress syndrome patient and lopinavir ritonavir: 1
- adaptive immune response and load reduction: 1
- adaptive immune response and lopinavir combination: 1
- adaptive immune response and lopinavir ritonavir: 1
- adaptive immune response and lopinavir ritonavir hydroxychloroquine: 1
- load reduction and lopinavir ritonavir: 1, 2, 3, 4
Co phrase search for related documents, hyperlinks ordered by date